Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA
暂无分享,去创建一个
A. Mocroft | O. Kirk | B. Clotet | L. Ruiz | S. Staszewski | C. Loveday | J. Lundgren | A. Monforte | A. Karlsson | A. Cozzi-Lepri | W. Bannister | L. Ruíz
[1] D. Richman,et al. 2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.
[2] M. Kozal,et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies , 2007, AIDS.
[3] L. Waters,et al. Non‐nucleoside reverse transcriptase inhibitors: a review , 2007, International journal of clinical practice.
[4] Deenan Pillay,et al. Update of the drug resistance mutations in HIV-1: Fall 2006. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[5] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[6] A. Mijch,et al. Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors. , 2004, Sexual health.
[7] Michael S Saag,et al. Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .
[8] Terri Wrin,et al. The prevalence of antiretroviral drug resistance in the United States , 2004, AIDS.
[9] Christopher D Pilcher,et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. , 2004, The New England journal of medicine.
[10] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[11] Gene D Morse,et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. , 2003, The New England journal of medicine.
[12] A. Mocroft,et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.
[13] K. Hertogs,et al. Extent and importance of cross-resistance to efavirenz after nevirapine failure. , 2002, AIDS research and human retroviruses.
[14] P. Keiser,et al. Comparison of Nevirapine- and Efavirenz-Containing Antiretroviral Regimens in Antiretroviral-Naïve Patients: A Cohort Study , 2002, HIV clinical trials.
[15] M. Moroni,et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. , 2002, The Journal of infectious diseases.
[16] B. Gazzard,et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study , 2002, AIDS.
[17] O. Kirk,et al. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients , 2001, AIDS.
[18] M. Mouroux,et al. Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen * , 2001, Journal of medical virology.
[19] C. Sabin,et al. Treatment comparisons in HIV infection: the benefits and limitations of observational cohort studies. , 2001, The Journal of antimicrobial chemotherapy.
[20] F. Brun-Vézinet,et al. Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial , 2001, Antiviral therapy.
[21] L. Bacheler,et al. Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy , 2000, Antimicrobial Agents and Chemotherapy.
[22] K. Tashima,et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.
[23] V. Soriano,et al. Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. , 1999, AIDS.
[24] K. Hertogs,et al. Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride , 1998, Antimicrobial Agents and Chemotherapy.
[25] D. Mayers. Drug-resistant HIV-1: the virus strikes back. , 1998, JAMA.
[26] J. Levy,et al. Plasma Viral Load, CD4+ Cell Counts, and HIV-1 Production by Cells , 1996, Science.
[27] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[28] INFECTIOUS DISEASES HOSPITAL , 1914 .
[29] N. Shulman,et al. NNRTI hypersusceptibility. , 2005, The AIDS reader.
[30] F. Castelli,et al. Genotype resistance profiles in patients failing an NNRTI‐containing regimen, and modifications after stopping NNRTI therapy , 2002, Journal of clinical laboratory analysis.